IRCT20220111053692N15尚未招募Unknown
Bioequivalence study of Bicalutomide 50 mg tablet (Iran Hormone) versus Casodex® 50 mg (AstraZeneca-Brand) Tablet in healthy volunteers
Iran Hormone pharmaceutical Co.0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- Male
入选标准
- •18 to 55 years old
- •Weight in range of 10 % proper body weight
- •All volunteers should be in a good health condition on the basis of medical history ,physical examination , routine blood test.
- •Possessing negative test for hepatitis B surface antigen (HBs-Ag), Antihepatitis-C antibody (anti-HCV) and anti-HIV.
- •Gender: male
排除标准
- •Volunteers with hypersensitivity to Bicalutomide were excluded.
- •Those with known history of drug abuse. alcohol consumer or cigarette smokers.
- •Taking medications that have drug interactions with Bicalutomide until one month before studying.
- •Disinclination to take the test
- •Blood donation or blood loss of more than 200 ml in the past month
研究者
相似试验
招募中
不适用
In-vivo Bioequivalence Test of Bicalutamide tablet with brand drugs (CASODEX® 150 mg AstraZeneca UK).Plasma drug concentration.IRCT20200105046010N45Sobhan Oncology Pharmaceutical CO.24
已完成
1 期
Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet in Healthy Subjects Under Fed ConditionsHealthyNCT01044706Kremers Urban Development Company60
已完成
1 期
Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex 50 mg Tablet in Healthy Subjects Under Fasting ConditionsBioequivalencyNCT01039233Kremers Urban Development Company60
已完成
1 期
Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fed ConditionsHealthyNCT00972855Teva Pharmaceuticals USA60
已完成
不适用
A clinical study of generic drug of bicalutamide on the efficacy and the safety in prostate cancer patientsProstate cancerJPRN-UMIN000005630Biwako health and welfare consortium60